Registry Study of Extracorporeal Blood Purification Therapy in Critically Ill Patients with Acute Kidney Injury or Multiorgan Failure

What this Trial Is About

Researchers are investigating the use of extracorporeal blood purification therapies EBPT in critically ill patients, especially those with acute kidney injury and multiorgan failure. EBPT is commonly used in critical care to remove inflammatory substances from the blood, aiming to improve organ function. However, previous clinical trials have not consistently shown benefits on long-term outcomes like 28-day or hospital mortality. This study aims to identify specific groups of patients who might benefit most from different EBPT membranes by collecting detailed clinical data. This observational study involves critically ill patients receiving various EBPT treatments for kidney support or immune system modulation, using commercial membranes as prescribed by their healthcare providers. Treatments include continuous renal replacement therapy, intermittent hemodialysis, hybrid therapies, and immunomodulation through special membranes that adsorb endotoxins or cytokines. Each center records detailed treatment settings and patient information via a web-based registry accessible on smartphones and tablets, which also provides helpful clinical tools for managing patient care. Participants will be observed throughout their EBPT treatment, with researchers gathering data on clinical and biochemical changes over time, including scoring systems and other patient characteristics. The main outcome is to identify which patient subpopulations benefit most from EBPT, measured 10 days after treatment starts. The registry allows centers to monitor their own results in real time and supports personalized treatment approaches. The study is ongoing and aims to improve understanding of how to tailor EBPT to individual patient needs while enhancing clinical practice through shared data.

Use of EBPT in Critically Ill Patients With AKI and/or Multiorgan Failure